Amandine Dernoncourt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amandine Dernoncourt has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Jean Schmidt
7 shared publicationsPierre Duhaut
Service de Médecine Interne et RECIF Centre Hospitalier Universitaire Amiens‐Picardie Amiens France
4 shared publicationsAnna Molto
Center for Research in Epidemiology and Statistics (CRESS), Université Paris Cité, Paris, France
3 shared publicationsGilles Kayem
Service de gynécologie obstétrique, hôpital Armand-Trousseau, Sorbonne université, AP-HP, 75012 Paris, France
3 shared publicationsLaurent Sailler
3 shared publicationsPauline Orquevaux
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Impact Of Preconception Counseling On Maternal And Neonatal Outcomes In 337 Prospective Pregnancies In Women With Systemic Lupus Erythematosus (French GR2 Study)
Background: Preconception counseling is recommended for women with systemic lupus erythematosus (SLE), but its association with pregnancy outcomes has not been prospectively evaluated. We aimed to assess the association between preconception counseling, adverse pregnancy outcomes, and SLE flares during pregnancy.Methods: We analyzed SLE pregnancies enrolled by 12 weeks of gestation in the prospective French GR2 cohort (2014–2024), continuing beyond 13 weeks, and compared outcomes according to preconception counseling status. The primary endpoint was the occurrence of at least one adverse pregnancy outcome (APO), defined as intrauterine fetal death, placental insufficiency leading to preterm delivery, severe small-for-gestational-age birth, or neonatal death. SLE flares and treatment-related outcomes were also assessed. Risks of APO and SLE flare were analyzed using Kaplan–Meier analyses and Cox proportional hazards models.Findings: Among 337 pregnancies, 251 (74.5%) were preceded by preconception counseling and 86 (25.5%) were not. Pregnancies were more frequently planned after counseling (208/239, 87.0% vs 36/77, 46.8%; p<0.001), treatment adherence was higher, and prednisone dose was lower. APOs occurred in 36/244 (14.8%) pregnancies after counseling versus 19/83 (22.9%) without counseling (p=0.09). After adjustment, counseling was associated with a lower risk of APOs (aHR 0.51 [0.28–0.92]; p=0.026). After exclusion of unplanned pregnancies, preconception counseling remained associated with a lower risk of APOs (aHR 0.43 [0.21–0.91]; p=0.029). SLE flares occurred in 27/225 (12.0%) versus 18/78 (23.1%) pregnancies (p=0.02), and counseling remained associated with a lower risk of flares (aHR 0.53 [0.28–0.99]; p=0.048).Interpretation: Preconception counseling was associated with lower risks of APOs and SLE flares during pregnancy. The association between counseling and a lower risk of APOs persisted after exclusion of unplanned pregnancies, suggesting that it extends beyond pregnancy planning alone. These findings support integrating preconception counseling into routine care for women with SLE planning pregnancy.
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact Of Preconception Counseling On Maternal And Neonatal Outcomes In 337 Prospective Pregnancies In Women With Systemic Lupus Erythematosus (French GR2 Study)
Background: Preconception counseling is recommended for women with systemic lupus erythematosus (SLE), but its association with pregnancy outcomes has not been prospectively evaluated. We aimed to assess the association between preconception counseling, adverse pregnancy outcomes, and SLE flares during pregnancy.Methods: We analyzed SLE pregnancies enrolled by 12 weeks of gestation in the prospective French GR2 cohort (2014–2024), continuing beyond 13 weeks, and compared outcomes according to preconception counseling status. The primary endpoint was the occurrence of at least one adverse pregnancy outcome (APO), defined as intrauterine fetal death, placental insufficiency leading to preterm delivery, severe small-for-gestational-age birth, or neonatal death. SLE flares and treatment-related outcomes were also assessed. Risks of APO and SLE flare were analyzed using Kaplan–Meier analyses and Cox proportional hazards models.Findings: Among 337 pregnancies, 251 (74.5%) were preceded by preconception counseling and 86 (25.5%) were not. Pregnancies were more frequently planned after counseling (208/239, 87.0% vs 36/77, 46.8%; p<0.001), treatment adherence was higher, and prednisone dose was lower. APOs occurred in 36/244 (14.8%) pregnancies after counseling versus 19/83 (22.9%) without counseling (p=0.09). After adjustment, counseling was associated with a lower risk of APOs (aHR 0.51 [0.28–0.92]; p=0.026). After exclusion of unplanned pregnancies, preconception counseling remained associated with a lower risk of APOs (aHR 0.43 [0.21–0.91]; p=0.029). SLE flares occurred in 27/225 (12.0%) versus 18/78 (23.1%) pregnancies (p=0.02), and counseling remained associated with a lower risk of flares (aHR 0.53 [0.28–0.99]; p=0.048).Interpretation: Preconception counseling was associated with lower risks of APOs and SLE flares during pregnancy. The association between counseling and a lower risk of APOs persisted after exclusion of unplanned pregnancies, suggesting that it extends beyond pregnancy planning alone. These findings support integrating preconception counseling into routine care for women with SLE planning pregnancy.
- Open Access
- 8 August 2026
- Published by Springer Nature in Reproductive Health
- Vol. 23 (1)
Chance of live birth in women with recurrent pregnancy loss referred to a French assisted reproductive technology center
- 8 August 2026
- Published by Springer Nature in Reproductive Health
- Vol. 23 (1)
Open AccessChance of live birth in women with recurrent pregnancy loss referred to a French assisted reproductive technology center
- Open Access
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002300
Maternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveys
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002300
Open AccessMaternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveys
- 13 December 2025
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 47 (1) , 20-31
Immunologie de la fécondation, de l’implantation et de la grossesse : Interactions clés et perspectives thérapeutiques
- 13 December 2025
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 47 (1) , 20-31
Immunologie de la fécondation, de l’implantation et de la grossesse : Interactions clés et perspectives thérapeutiques
- Open Access
- 4 September 2025
- Published by Elsevier in Revue du Rhumatisme
- Vol. 93 (2) , 244-250
Traitements rhumatologiques et grossesse
- 4 September 2025
- Published by Elsevier in Revue du Rhumatisme
- Vol. 93 (2) , 244-250
Open AccessTraitements rhumatologiques et grossesse
- Open Access
- 27 December 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 46 (4) , 220-228
Utilisation de l’hydroxychloroquine dans les pathologies obstétricales récurrentes à médiation immune (en dehors du lupus systémique) : fondements et preuves scientifiques
- 27 December 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 46 (4) , 220-228
Open AccessUtilisation de l’hydroxychloroquine dans les pathologies obstétricales récurrentes à médiation immune (en dehors du lupus systémique) : fondements et preuves scientifiques
- 19 December 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (5) , 614-624
Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population‐Based Study
Objective: To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE). Design: Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014‐ongoing). Setting: Seventy‐six centres in France. Population: All pregnancies in women with SLE enrolled in the GR2 study, conceived before 1 August 2022, with available end‐of‐pregnancy data and known conception type, were included; that is, 577 spontaneous and 53 assisted pregnancies. Methods: A comparative analysis of spontaneous and assisted pregnancies was conducted. Logistic regression was used to determine if fertility treatments were independently associated with live birth prognosis, adjusting for confounders (e.g., maternal age). Kaplan–Meier analysis compared cumulative incidences of disease flares and adverse pregnancy outcomes (APOs), with confounding factors adjusted using a Cox regression model. Main Outcome Measures: Live birth, disease flares, and APOs. Results: The mean age was older (35.8 vs. 32.3 years, p < 1 × 10 −4 ), and twins were more frequent in assisted pregnancies (5/50, 10.0% vs. 20/554, 3.6%; p = 0.047). Lupus disease was clinically inactive at baseline in 51 (96.2%) assisted pregnancies (vs. n = 511, 89.6%; p = 0.15), with 35 of 45 (77.8%) having no chronic damage (vs. 448/513, 87.3%; p = 0.07). The live birth rate was similar between assisted and spontaneous pregnancies ( n = 46, 86.8% vs. n = 505, 87.5%; p = 0.83), with no statistical difference in the incidence of lupus flares and APOs. These results remained consistent after adjusting for confounding factors. Conclusions: Fertility treatments in women with mostly well‐controlled SLE did not appear to increase risks of maternal and neonatal complications, supporting current recommendations. Trial Registration ClinicalTrials.gov identifier: NCT02450396
- 19 December 2024
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (5) , 614-624
Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population‐Based Study
Objective: To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE). Design: Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014‐ongoing). Setting: Seventy‐six centres in France. Population: All pregnancies in women with SLE enrolled in the GR2 study, conceived before 1 August 2022, with available end‐of‐pregnancy data and known conception type, were included; that is, 577 spontaneous and 53 assisted pregnancies. Methods: A comparative analysis of spontaneous and assisted pregnancies was conducted. Logistic regression was used to determine if fertility treatments were independently associated with live birth prognosis, adjusting for confounders (e.g., maternal age). Kaplan–Meier analysis compared cumulative incidences of disease flares and adverse pregnancy outcomes (APOs), with confounding factors adjusted using a Cox regression model. Main Outcome Measures: Live birth, disease flares, and APOs. Results: The mean age was older (35.8 vs. 32.3 years, p < 1 × 10 −4 ), and twins were more frequent in assisted pregnancies (5/50, 10.0% vs. 20/554, 3.6%; p = 0.047). Lupus disease was clinically inactive at baseline in 51 (96.2%) assisted pregnancies (vs. n = 511, 89.6%; p = 0.15), with 35 of 45 (77.8%) having no chronic damage (vs. 448/513, 87.3%; p = 0.07). The live birth rate was similar between assisted and spontaneous pregnancies ( n = 46, 86.8% vs. n = 505, 87.5%; p = 0.83), with no statistical difference in the incidence of lupus flares and APOs. These results remained consistent after adjusting for confounding factors. Conclusions: Fertility treatments in women with mostly well‐controlled SLE did not appear to increase risks of maternal and neonatal complications, supporting current recommendations. Trial Registration ClinicalTrials.gov identifier: NCT02450396
- Open Access
- 28 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (9) , 1934-1941
Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry
What are the outcomes of pregnancies exposed to hydroxychloroquine (HCQ) in women with a history of recurrent pregnancy loss (RPL), and what factors predict the course of these pregnancies beyond the first trimester? In our cohort of pregnancies in women with a history of RPL exposed to HCQ early in pregnancy, we found that the only factor determining the success of these pregnancies was the number of previous miscarriages. Dysregulation of the maternal immune system plays a role in RPL. HCQ, with its dual immunomodulating and vascular protective effects, is a potential treatment for unexplained RPL. The FALCO (Facteurs de récidive précoce des fausses couches) registry is an ongoing French multicenter infertility registry established in 2017 that includes women (aged from 18 to 49 years) with a history of spontaneous RPL (at least three early miscarriages (≤12 weeks of gestation (WG)) recruited from several university hospitals. Spontaneous pregnancies enrolled in the FALCO registry with an exposure to HCQ (before conception or at the start of pregnancy) were included. Pregnancies concomitantly exposed to tumor necrosis factor inhibitors, interleukin-1 and -2 inhibitors, intravenous immunoglobulin, and/or intravenous intralipid infusion, were excluded. Concomitant treatment with low-dose aspirin (LDA), low-molecular weight heparin (LMWH), progesterone, and/or prednisone was allowed. All patients underwent the recommended evaluations for investigating RPL. Those who became pregnant received obstetric care in accordance with French recommendations and were followed prospectively. The main endpoint was the occurrence of a pregnancy continuing beyond 12 WG, and the secondary endpoint was the occurrence of a live birth. One hundred pregnancies with HCQ exposure in 74 women were assessed. The mean age of the women was 34.2 years, and the median number of previous miscarriages was 5. Concomitant exposure was reported in 78 (78%) pregnancies for prednisone, 56 (56%) pregnancies for LDA, and 41 (41%) pregnancies for LMWH. Sixty-two (62%) pregnancies ended within 12 WG, the other 38 (38%) continuing beyond 12 WG. The risk of experiencing an additional early spontaneous miscarriage increased with the number of previous miscarriages, but not with age. The distributions of anomalies identified in RPL investigations and of exposure to other drugs were similar between pregnancies lasting ≤12 WG and those continuing beyond 12WG. The incidence of pregnancies progressing beyond 12 WG was not higher among pregnancies with at least one positive autoantibody (Ab) (i.e. antinuclear Ab titer ≥1:160, ≥1 positive conventional and/or non-conventional antiphospholipid Ab, and/or positive results for ≥1 antithyroid Ab) without diminished ovarian reserve (18/51, 35.3%) than among those without such autoantibody (18/45, 40.0%) (P = 0.63). Multivariate analysis showed that having ≤4 prior miscarriages was the only factor significantly predictive for achieving a pregnancy > 12 WG, after adjustment for age and duration of HCQ use prior to conception (adjusted odds ratio (OR) = 3.13 [1.31–7.83], P = 0.01). Our study has limitations, including the absence of a control group, incomplete data for the diagnostic procedure for RPL in some patients, and the unavailability of results from endometrial biopsies, as well as information about paternal age and behavioral factors. Consequently, not all potential confounding factors could be considered. Exposure to HCQ in early pregnancy for women with a history of RPL does not seem to prevent further miscarriages, suggesting limited impact on mechanisms related to the maternal immune system. The research received no specific funding, and the authors declare no competing interests. clinicaltrial.gov NCT05557201.
- 28 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (9) , 1934-1941
Open AccessHydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry
What are the outcomes of pregnancies exposed to hydroxychloroquine (HCQ) in women with a history of recurrent pregnancy loss (RPL), and what factors predict the course of these pregnancies beyond the first trimester? In our cohort of pregnancies in women with a history of RPL exposed to HCQ early in pregnancy, we found that the only factor determining the success of these pregnancies was the number of previous miscarriages. Dysregulation of the maternal immune system plays a role in RPL. HCQ, with its dual immunomodulating and vascular protective effects, is a potential treatment for unexplained RPL. The FALCO (Facteurs de récidive précoce des fausses couches) registry is an ongoing French multicenter infertility registry established in 2017 that includes women (aged from 18 to 49 years) with a history of spontaneous RPL (at least three early miscarriages (≤12 weeks of gestation (WG)) recruited from several university hospitals. Spontaneous pregnancies enrolled in the FALCO registry with an exposure to HCQ (before conception or at the start of pregnancy) were included. Pregnancies concomitantly exposed to tumor necrosis factor inhibitors, interleukin-1 and -2 inhibitors, intravenous immunoglobulin, and/or intravenous intralipid infusion, were excluded. Concomitant treatment with low-dose aspirin (LDA), low-molecular weight heparin (LMWH), progesterone, and/or prednisone was allowed. All patients underwent the recommended evaluations for investigating RPL. Those who became pregnant received obstetric care in accordance with French recommendations and were followed prospectively. The main endpoint was the occurrence of a pregnancy continuing beyond 12 WG, and the secondary endpoint was the occurrence of a live birth. One hundred pregnancies with HCQ exposure in 74 women were assessed. The mean age of the women was 34.2 years, and the median number of previous miscarriages was 5. Concomitant exposure was reported in 78 (78%) pregnancies for prednisone, 56 (56%) pregnancies for LDA, and 41 (41%) pregnancies for LMWH. Sixty-two (62%) pregnancies ended within 12 WG, the other 38 (38%) continuing beyond 12 WG. The risk of experiencing an additional early spontaneous miscarriage increased with the number of previous miscarriages, but not with age. The distributions of anomalies identified in RPL investigations and of exposure to other drugs were similar between pregnancies lasting ≤12 WG and those continuing beyond 12WG. The incidence of pregnancies progressing beyond 12 WG was not higher among pregnancies with at least one positive autoantibody (Ab) (i.e. antinuclear Ab titer ≥1:160, ≥1 positive conventional and/or non-conventional antiphospholipid Ab, and/or positive results for ≥1 antithyroid Ab) without diminished ovarian reserve (18/51, 35.3%) than among those without such autoantibody (18/45, 40.0%) (P = 0.63). Multivariate analysis showed that having ≤4 prior miscarriages was the only factor significantly predictive for achieving a pregnancy > 12 WG, after adjustment for age and duration of HCQ use prior to conception (adjusted odds ratio (OR) = 3.13 [1.31–7.83], P = 0.01). Our study has limitations, including the absence of a control group, incomplete data for the diagnostic procedure for RPL in some patients, and the unavailability of results from endometrial biopsies, as well as information about paternal age and behavioral factors. Consequently, not all potential confounding factors could be considered. Exposure to HCQ in early pregnancy for women with a history of RPL does not seem to prevent further miscarriages, suggesting limited impact on mechanisms related to the maternal immune system. The research received no specific funding, and the authors declare no competing interests. clinicaltrial.gov NCT05557201.
- Open Access
- 15 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers
Purpose: To assess the diagnostic performance of a panel of standard tumor markers (TMs) in patients hospitalized with significant involuntary weight loss (IWL) and elevated levels of inflammation biomarkers, and a combination of the TM panel and the finding of the computed tomography (CT) scan. Methods: We conducted a retrospective study in the internal medicine department at Amiens-Picardie University Medical Center (Amiens, France) between January 1st, 2015, and November 1st, 2021. The inclusion criteria were age 18 or over, significant IWL (≥ 5 kg over 6 months), elevated inflammation biomarkers (e.g. C-reactive protein), and assay data on two or more standard TMs (carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19 − 9, CA 15 − 3, CA 125, neuron-specific enolase (NSE), alpha-fetoprotein (AFP), calcitonin, and prostate-specific antigen (PSA)). The result of each TM assay was interpreted qualitatively (as positive or negative), according to our central laboratory’s usual thresholds. Results: Cancer was diagnosed in 50 (37.0%) of the 135 patients included. Positivity for one or more TMs had a positive predictive value (PPV) of 0.55 [0.43–0.66], and a negative predictive value (NPV) of 0.84 [0.75–0.93] for cancer diagnosis. When combined with the presence of suspicious CT findings (e.g. a mass, enlarged lymph nodes and/or effusion), positivity for one or more TMs had a PPV of 0.92 [0.08–0.30]. In the absence of suspicious CT findings, a fully negative TM panel had an NPV of 0.96 [0.89-1.00]. Conclusion: A negative TM panel argues against the presence of a cancer, especially in the absence of suspicious CT findings.
- 15 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessRelevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers
Purpose: To assess the diagnostic performance of a panel of standard tumor markers (TMs) in patients hospitalized with significant involuntary weight loss (IWL) and elevated levels of inflammation biomarkers, and a combination of the TM panel and the finding of the computed tomography (CT) scan. Methods: We conducted a retrospective study in the internal medicine department at Amiens-Picardie University Medical Center (Amiens, France) between January 1st, 2015, and November 1st, 2021. The inclusion criteria were age 18 or over, significant IWL (≥ 5 kg over 6 months), elevated inflammation biomarkers (e.g. C-reactive protein), and assay data on two or more standard TMs (carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19 − 9, CA 15 − 3, CA 125, neuron-specific enolase (NSE), alpha-fetoprotein (AFP), calcitonin, and prostate-specific antigen (PSA)). The result of each TM assay was interpreted qualitatively (as positive or negative), according to our central laboratory’s usual thresholds. Results: Cancer was diagnosed in 50 (37.0%) of the 135 patients included. Positivity for one or more TMs had a positive predictive value (PPV) of 0.55 [0.43–0.66], and a negative predictive value (NPV) of 0.84 [0.75–0.93] for cancer diagnosis. When combined with the presence of suspicious CT findings (e.g. a mass, enlarged lymph nodes and/or effusion), positivity for one or more TMs had a PPV of 0.92 [0.08–0.30]. In the absence of suspicious CT findings, a fully negative TM panel had an NPV of 0.96 [0.89-1.00]. Conclusion: A negative TM panel argues against the presence of a cancer, especially in the absence of suspicious CT findings.
- 27 November 2023
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 44, A561-A562
Un plasmocytome de la base du crâne mimant une artérite à cellules géantes
- 27 November 2023
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 44, A561-A562
Un plasmocytome de la base du crâne mimant une artérite à cellules géantes